213 related articles for article (PubMed ID: 26310247)
21. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
[TBL] [Abstract][Full Text] [Related]
22. Nano-strategies as Oral Drug Delivery Platforms for Treatment of Cancer: Challenges and Future Perspectives.
Quadir SS; Saharan V; Choudhary D; Harish ; Jain CP; Joshi G
AAPS PharmSciTech; 2022 May; 23(5):152. PubMed ID: 35606661
[TBL] [Abstract][Full Text] [Related]
23. The intravenous to oral switch of taxanes: strategies and current clinical developments.
Vermunt MA; Bergman AM; der Putten EV; Beijnen JH
Future Oncol; 2021 Apr; 17(11):1379-1399. PubMed ID: 33356545
[TBL] [Abstract][Full Text] [Related]
24. Prodrugs as drug delivery system in oncology.
Delahousse J; Skarbek C; Paci A
Cancer Chemother Pharmacol; 2019 Nov; 84(5):937-958. PubMed ID: 31392391
[TBL] [Abstract][Full Text] [Related]
25. Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents.
Anaya-Ruiz M; Bandala C; Landeta G; Martínez-Morales P; Zumaquero-Rios JL; Sarracent-Pérez J; Pérez-Santos M
Recent Pat Anticancer Drug Discov; 2019; 14(1):85-94. PubMed ID: 30381087
[TBL] [Abstract][Full Text] [Related]
26. Recent trends in oral drug delivery: a review.
Gupta H; Bhandari D; Sharma A
Recent Pat Drug Deliv Formul; 2009 Jun; 3(2):162-73. PubMed ID: 19519576
[TBL] [Abstract][Full Text] [Related]
27. Nanocapsules for Drug Delivery: An Updated Review of the Last Decade.
Erdoğar N; Akkın S; Bilensoy E
Recent Pat Drug Deliv Formul; 2018; 12(4):252-266. PubMed ID: 30674269
[TBL] [Abstract][Full Text] [Related]
28. Amorphous Solid Dispersions or Prodrugs: Complementary Strategies to Increase Drug Absorption.
Rumondor ACF; Dhareshwar SS; Kesisoglou F
J Pharm Sci; 2016 Sep; 105(9):2498-2508. PubMed ID: 26886316
[TBL] [Abstract][Full Text] [Related]
29. Preclinical studies of dendrimer prodrugs.
Kojima C
Expert Opin Drug Metab Toxicol; 2015; 11(8):1303-15. PubMed ID: 26028253
[TBL] [Abstract][Full Text] [Related]
30. Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy.
Dragojevic S; Ryu JS; Raucher D
Molecules; 2015 Dec; 20(12):21750-69. PubMed ID: 26690101
[TBL] [Abstract][Full Text] [Related]
31. Prodrugs for transdermal drug delivery - trends and challenges.
Ita KB
J Drug Target; 2016 Sep; 24(8):671-8. PubMed ID: 26878159
[TBL] [Abstract][Full Text] [Related]
32. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
33. Nanoparticles for tumor targeted therapies and their pharmacokinetics.
Wang J; Sui M; Fan W
Curr Drug Metab; 2010 Feb; 11(2):129-41. PubMed ID: 20359289
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy.
Sun B; Luo C; Cui W; Sun J; He Z
J Control Release; 2017 Oct; 264():145-159. PubMed ID: 28844757
[TBL] [Abstract][Full Text] [Related]
35. Current prodrug design for drug discovery.
Hsieh PW; Hung CF; Fang JY
Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
[TBL] [Abstract][Full Text] [Related]
36. The Sojourn from Parenteral to Oral Taxanes using Nanocarrier Systems: A Patent Review.
Khurana RK; Mahajan M; Teenu ; Kapoor S; Jain S; Singh B
Recent Pat Drug Deliv Formul; 2016; 10(1):44-58. PubMed ID: 26427603
[TBL] [Abstract][Full Text] [Related]
37. Redox sensitive lipid-camptothecin conjugate encapsulated solid lipid nanoparticles for oral delivery.
Du Y; Ling L; Ismail M; He W; Xia Q; Zhou W; Yao C; Li X
Int J Pharm; 2018 Oct; 549(1-2):352-362. PubMed ID: 30099214
[TBL] [Abstract][Full Text] [Related]
38. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance.
Saneja A; Khare V; Alam N; Dubey RD; Gupta PN
Expert Opin Drug Deliv; 2014 Jan; 11(1):121-38. PubMed ID: 24295039
[TBL] [Abstract][Full Text] [Related]
39. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.
Hayashi JY; Tamanoi F
Enzymes; 2017; 42():153-172. PubMed ID: 29054269
[TBL] [Abstract][Full Text] [Related]
40. Recent patents on oral insulin delivery.
Navgire SD; Satpute AS; Pandey S; Patil AT
Recent Pat Drug Deliv Formul; 2014; 8(3):202-5. PubMed ID: 24981288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
